Liminatus Pharma, Inc. Class A Common Stock (LIMN) — Net Asset Quality Index
Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a Net Asset Quality Index of -1914.0% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $512.79K minus total liabilities of $10.33 Million yields net assets of $-9.81 Million. A higher index indicates a stronger, lower-leverage balance sheet. Also explore LIMN current and non-current assets for the complete picture of this company's asset base.
Quality Index
Net Assets
Total Assets
Total Liabilities
Liminatus Pharma, Inc. Class A Common Stock Net Asset Quality Index Over Time (2021–2025)
This chart shows how Liminatus Pharma, Inc. Class A Common Stock's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at -1914.0%, representing net assets of $-9.81 Million against total assets of $512.79K USD. See LIMN net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see how much is Liminatus Pharma, Inc. Class A Common St worth.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -1914.0% | $-9.81 Million | $512.79K | $10.33 Million | ▼ -1353.0 pp |
| 2024 | -561.0% | $-15.87 Million | $2.83 Million | $18.70 Million | ▼ -323.5 pp |
| 2023 | -237.5% | $-10.69 Million | $4.50 Million | $15.19 Million | ▼ -245.9 pp |
| 2022 | 8.4% | $1.29 Million | $15.49 Million | $14.19 Million | ▼ -83.8 pp |
| 2021 | 92.2% | $254.87 Million | $276.44 Million | $21.57 Million | — |